Biocon Limited has successfully completed its Qualified Institutions Placement (QIP), with the Fund Raising Committee announcing the closure and allotment of equity shares on January 14, 2026. The pharmaceutical company raised significant capital through this institutional placement, demonstrating strong investor confidence in its growth prospects.

QIP Details and Pricing Structure

The company's Fund Raising Committee, in its meeting held on January 14, 2026, approved the allocation of shares to qualified institutional buyers. The key parameters of the placement are outlined below:

The total fundraising from this QIP amounts to approximately ₹4,151 crores, calculated based on the allotted shares and issue price. The pricing was determined in accordance with the formula prescribed under Regulation 176(1) of the SEBI ICDR Regulations.

Timeline and Regulatory Compliance

The QIP demonstrated efficient execution with a swift timeline from opening to closure:

• Issue Opening: January 12, 2026
• Issue Closure: January 14, 2026
• Committee Meeting Duration: 10:00 PM to 10:10 PM on January 14, 2026

The Fund Raising Committee's meeting addressed three critical resolutions during the brief 10-minute session. The committee approved the closure of the issue following receipt of application forms and funds in the escrow account from eligible qualified institutional buyers. Additionally, they determined and approved the allocation of shares according to SEBI ICDR Regulations and finalized confirmation of allocation notes to be sent to successful institutional investors.

Regulatory Framework and Approvals

The QIP was conducted under comprehensive regulatory oversight, ensuring compliance with multiple statutory requirements. The placement was executed under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, along with Sections 42, 23(1)(b), and 62(1)(c) of the Companies Act, 2013.

Biocon has fulfilled its disclosure obligations under Regulation 30 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has made the intimation available on its website at www.biocon.com , ensuring transparency for all stakeholders.

Market Communication

The company formally communicated the QIP completion to both major stock exchanges where its shares are listed. Biocon submitted detailed notifications to BSE Limited (Scrip Code: 532523) and National Stock Exchange of India Limited (Scrip Symbol: BIOCON), maintaining compliance with listing requirements and ensuring proper market disclosure of this significant capital raising activity.

Biocon Limited has announced its upcoming board meeting and earnings conference call schedule for the third quarter of fiscal year 2025-26. The company has informed stock exchanges about these important corporate events through a regulatory filing dated January 13, 2026.

Board Meeting and Financial Results

The Board of Directors of Biocon Limited is scheduled to meet on Thursday, February 12, 2026 to approve and take on record the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. This meeting is being conducted in compliance with Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Trading Window Closure

In accordance with the company's Code of Conduct for Prevention of Insider Trading and SEBI regulations, the trading window for dealing in Biocon's securities has been closed from Thursday, January 1, 2026 to Saturday, February 14, 2026 (both days inclusive). The trading window will reopen on Sunday, February 15, 2026.

Earnings Conference Call Details

Following the board meeting, Biocon will organize an earnings conference call for analysts and investors to discuss the Q3FY26 results. The conference call details are as follows:

Recording and Transcript Availability

The company has outlined a comprehensive schedule for making call recordings and transcripts available to stakeholders:

• Audio Recording: Will be available before the next trading day or within 24 hours from the end of the call, whichever is earlier
• Video Recording: Will be made available within 48 hours from the end of the call
• Conference Call Transcript: Will be available within 5 working days of the call's conclusion

All recordings and transcripts will be accessible on the company website under the sections: Biocon > Investors > Financial Information > Earnings Call Recordings and Earnings Call Transcripts respectively.

Contact Information

For further information regarding the earnings conference call, stakeholders can contact Prashant Nair, Investor Relations at Biocon Biologics Limited, at +91 80 2808 2040 or +91 98200 95476, or via email at prashant.nair@biocon.com . The regulatory filing was signed by Rajesh U. Shanoy, Company Secretary and Compliance Officer.